Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Atypical HUS: time to take stock of current guidelines and outcome measures?

Pediatric nephrology (Berlin, Germany) - 1 May 2013

Rees Lesley

Abstract excerpt

European guidelines for the assessment and management of atypical HUS were written in 2009. Since then our understanding of this group of diseases has advanced. Evidence is emerging that eculizumab, a monoclonal antibody inhibiting C5 activation, is effective, and potentially superior to current treatment with plasmapheresis. The evidence base for the benefits of plasmapheresis consists of case series and small...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Atypical Hemolytic Uremic Syndrome
Share to Clinical Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Complement Activation

Share to Hemolytic-Uremic Syndrome

Share to Practice Guidelines as Topic

Share to Risk Factors

Share to Treatment Outcome

Source

Identifiers

PMID: 23389238
DOI: 10.1007/s00467-013-2423-x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Atypical HUS: time to take stock of current guidelines and outcome measures?PMID 23389238Read ↗

An update for atypical haemolytic uraemic syndrome: Diagnosis and treatment. A consensus documentSemantic proximity Read ↗

How I diagnose and treat atypical hemolytic uremic syndromeSemantic proximity Read ↗

Multidisciplinary consensus on the diagnosis and management of patients with atypical Hemolytic Uremic Syndrome (complement-mediated TMA): Recommendations from Italian scientific societies, patient associations and regulatorsSemantic proximity Read ↗

Atypical hemolytic uremic syndrome.Semantic proximity Read ↗

Improved Renal Recovery with Eculizumab Therapy among Children with High Prevalence of Mutation-Associated Atypical Hemolytic Uremic Syndrome: A Retrospective Cohort Study.Semantic proximity Read ↗

Atypical Hemolytic Uremic Syndrome: A Meta-Analysis of Case Reports Confirms the Prevalence of Genetic Mutations and the Shift of Treatment Regimens.Semantic proximity Read ↗

Pediatric Atypical Hemolytic Uremic Syndrome Advances.Semantic proximity Read ↗

Turkish pediatric atypical hemolytic uremic syndrome registry: initial analysis of 146 patients.Semantic proximity Read ↗

A new era in the diagnosis and treatment of atypical haemolytic uraemic syndrome.Semantic proximity Read ↗

Safety and effectiveness of eculizumab for adult patients with atypical hemolytic-uremic syndrome in Japan: interim analysis of post-marketing surveillance.Semantic proximity Read ↗

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)Semantic proximity Read ↗

A complicated case of atypical hemolytic uremic syndrome with frequent relapses under eculizumab.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.